Wockhardt
Drug Manufacturers - Specialty & Generic · WOCKPHARMA
Mid CapHealthcareDistressed / Turnaround
Dr. Murtaza Khorakiwala
Managing Director · Visionary
Company DNA
Founder-Centric
About
Wockhardt is a Mid Cap company in the Healthcare sector, listed on NSE as WOCKPHARMA. With a market cap of ₹21K Cr and revenue of ₹3K Cr, it is currently in the Distressed / Turnaround phase. Known for its Founder-Centric culture and Fast-Follower approach to innovation, the company operates at a Seasonal-Burst pace. A family-led pharmaceutical firm currently undergoing significant strategic pivots, with the founder-MD heavily involved in turnaround efforts. Its strategic mandate: Mandatory stabilization of the balance sheet and operational efficiency to restore profitability after years of market volatility.
FAQ
What kind of company is Wockhardt?
Wockhardt is a Mid Cap Healthcare company (WOCKPHARMA) in the Distressed / Turnaround phase with a market cap of ₹21K Cr. It is classified as Founder-Centric in culture.
What is Wockhardt's culture and work environment like?
Wockhardt has a Founder-Centric culture with Fast-Follower innovation DNA and a Seasonal-Burst pace of execution. Employee brand: Learning Ground. Customer relationship style: B2B-Enterprise. A family-led pharmaceutical firm currently undergoing significant strategic pivots, with the founder-MD heavily involved in turnaround efforts.
Who leads Wockhardt?
Wockhardt is led by Dr. Murtaza Khorakiwala (Managing Director), a Visionary leader with 27 years of experience.
What are Wockhardt's financials?
Wockhardt reported revenue of ₹3K Cr in FY25 with a 5-year revenue CAGR of -3.2%. Operating margin: 6.2%. Market cap: ₹21K Cr.
Culture & Strategy
CultureFounder-Centric
InnovationFast-Follower
PaceSeasonal-Burst
PurposePurpose-Blended
CustomerB2B-Enterprise
EmployeeLearning Ground
BrandTechnical-Expert
LifecycleDistressed / Turnaround
A family-led pharmaceutical firm currently undergoing significant strategic pivots, with the founder-MD heavily involved in turnaround efforts.
Mandate
Mandatory stabilization of the balance sheet and operational efficiency to restore profitability after years of market volatility.
Mandatory stabilization of the balance sheet and operational efficiency to restore profitability after years of market volatility.
Financials
Revenue FY25₹3K Cr
PAT FY25₹-470000000
Rev CAGR 5Y-3.2%
OPM6.2%
NPM-1.6%
ROE-1.1%
ROCE3%
P/E910.8
Fwd P/E—
P/B4.3
D/E50.4
Mkt Cap₹21K Cr
Promoter51%
Institutional14.8%
Similar Culture
.png)
Could You Lead Wockhardt?
Take the Genome Benchmark →